Trial Profile
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jan 2020 Results published in the Gynecologic Oncology
- 05 Jun 2018 Results (n=25) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 30 May 2018 Planned primary completion date changed from 31 Mar 2018 to 31 Dec 2018.